Autolus Therapeutics plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Autolus Therapeutics plc
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.
Arix Biosciences has unveiled three significant changes to the organization, including the appointment of Christian Schetter as co-managing director, which the healthcare-focused venture capitalist hopes will keep its impressive record of biotech investments on track.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Autolus Limited